 |
G. Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. In 2002, Mr. Burrill was recognized as a biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). He currently serves on a number of boards of directors including DepoMed (Amex: DMI), Galapagos Genomics, NC-based Targacept, and Third Wave Technologies (NASDAQ: TWTI), and is chairman of the boards of NC-based Paradigm Genetics (NASDAQ: PDGM) and Pyxis Genomics. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm’s worldwide services to clients in the biotechnology, life sciences, high technology and manufacturing industries. |
 |
Dr. Leroy Hood is widely recognized as one of the world’s leading scientists in molecular biotechnology and genomics. Early in his professional career at the California Institute of Technology, Dr. Hood and his colleagues initiated four instruments - the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer - which comprise the technological foundation for contemporary molecular biology. One of these instruments has also revolutionized genomics by allowing the rapid automated sequencing of DNA. In 2000, Dr. Hood co-founded the Seattle-based Institute for Systems Biology to pioneer systems approaches to biology and medicine. He has also been involved in the founding of numerous biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta and serves on the board of NC-based Paradigm Genetics. |
 |
Internationally recognized for his contributions in inflammation research, Dr. Ralph Snyderman has also overseen the development of the Duke University Health System -- one of the few fully integrated academic health systems in the country. After rising through the medical ranks at Duke University early in his career, Dr. Snyderman left Duke in 1987 to join Genentech, Inc. as vice president for medical research and development. A year later, he was promoted to senior vice president. While at Genentech, he led the development and licensing of a number of novel therapeutics and supervised 300 staff members working in pharmacology, clinical research and regulatory affairs. |